These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1791 related items for PubMed ID: 23040435

  • 1. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, Szabo Z, Jaeger U.
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [Abstract] [Full Text] [Related]

  • 2. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS.
    J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
    [Abstract] [Full Text] [Related]

  • 3. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
    Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, Jaeger U, Verhoef G, Schwenkglenks M, Bacon P, Bendall K, Lugtenburg PJ.
    Leuk Res; 2012 May; 36(5):548-53. PubMed ID: 22385870
    [Abstract] [Full Text] [Related]

  • 4. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U, Angrili F, DeCosta L, Wetten S, Federico M.
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [Abstract] [Full Text] [Related]

  • 5. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

  • 6. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
    Wieringa A, Boslooper K, Hoogendoorn M, Joosten P, Beerden T, Storm H, Kibbelaar RE, Veldhuis GJ, van Kamp H, van Rees B, Kluin-Nelemans HC, Veeger NJ, van Roon EN.
    Br J Haematol; 2014 May 25; 165(4):489-96. PubMed ID: 24754632
    [Abstract] [Full Text] [Related]

  • 7. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.
    Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, Dührsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U.
    Support Care Cancer; 2012 Mar 25; 20(3):647-52. PubMed ID: 22101611
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
    Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.
    Lancet Oncol; 2013 May 25; 14(6):525-33. PubMed ID: 23578722
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
    Morrison VA, Weller EA, Habermann TM, Li S, Fisher RI, Cheson BD, Peterson BA.
    Leuk Lymphoma; 2017 Aug 25; 58(8):1814-1822. PubMed ID: 27967294
    [Abstract] [Full Text] [Related]

  • 12. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ, Chung JS, Song MK, Kim SK, Choe S, Cho GJ.
    Cancer Chemother Pharmacol; 2012 May 25; 69(5):1165-72. PubMed ID: 22215473
    [Abstract] [Full Text] [Related]

  • 13. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH, Delgado DJ.
    Cancer; 2003 Dec 01; 98(11):2402-9. PubMed ID: 14635075
    [Abstract] [Full Text] [Related]

  • 14. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
    Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators.
    Lancet Oncol; 2011 May 01; 12(5):460-8. PubMed ID: 21482186
    [Abstract] [Full Text] [Related]

  • 15. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
    Balducci L, Mo M, Abella E, Saven A.
    Am J Clin Oncol; 2014 Dec 01; 37(6):603-10. PubMed ID: 25350463
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
    Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM.
    Support Care Cancer; 2014 Aug 01; 22(8):2167-75. PubMed ID: 24652049
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
    Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R.
    Br J Haematol; 2012 Oct 01; 159(1):39-49. PubMed ID: 22849793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.